The value of D-dimer in lung transplant recipients with bronchiolitis obliterans syndrome  by Shitrit, David et al.
ARTICLE IN PRESS
Respiratory Medicine (2008) 102, 205–2090954-6111/$ - see fro
doi:10.1016/j.rmed.
Abbreviations: BO
activator inhibitor; T
Corresponding au
fax: +972 3 937 7142.
E-mail address: dThe value of D-dimer in lung transplant recipients
with bronchiolitis obliterans syndrome
David Shitrita,b,, Anat Amitala,b, Ben Foxa,b, Mordechai R. Kramera,baPulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqva 49100, Israel
bSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Received 18 June 2007; accepted 22 September 2007
Available online 31 October 2007KEYWORDS
D-dimer;
Lung transplantation;
Bronchiolitis
obliterans syndrome;
Functional exercise
capacitynt matter & 2007
2007.09.010
S, bronchiolitis ob
PA, tissue plasmin
thor. Pulmonary I
avids3@clalit.org.Summary
Bronchiolitis obliterans syndrome (BOS) following lung transplantation is common and
potentially devastating. Its exact cause is undefined, but multiple immune and nonimmune
processes contribute to its pathogenesis. The diagnosis of BOS syndrome is based on
clinical presentation of progressive decline in the lung functions together with appropriate
pathological findings. Severe acute rejection and recurrent acute rejection have been
shown to confer the greatest risk for obliterative bronchiolitis, signifying the central
importance of alloimmunity in the disease process. BOS is associated with activation of the
coagulation system, and is a major cause of lung allograft loss. The aim of the study was to
determine if there is an association between D-dimer levels and functional exercise
capacity in lung transplant recipients with BOS.
This prospective group comparison study was conducted at a tertiary-care, university-
affiliated medical center. The sample included 46 patients (29%) who underwent lung
transplantation between January 1997 and May 2006 and had positive findings on screening
for BOS. Blood samples were collected for measurement of plasma D-dimer levels by the
rapid MiniQuant assay. Correlational analysis was used to determine the association of
D-dimer levels with demographic clinical data, pulmonary function, and functional
exercise capacity parameters, including the 6-min walk test and cardiopulmonary exercise
testing.
D-dimer levels were associated with FEV1 (r ¼ 0.43, p ¼ 0.001), 6-min walk test
(r ¼ 0.53, p ¼ 0.04), and VO2/kg/min (r ¼ 0.36, p ¼ 0.04). No correlations were noted
between D-dimer levels and total lung capacity, diffusion capacity, and oxygen saturation.
On multivariate logistic regression, only FEV1 was a significant predictor of BOS (OR 0.885,
CI: 0.812–0.965).Elsevier Ltd. All rights reserved.
literans syndrome; FEV1, forced expiratory volume in 1 s; 6MWT, 6-min walk test; PAI-I, plasminogen
ogen activation; VO2, oxygen consumption
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D. Shitrit et al.206We conclude that in lung transplant recipients with BOS, D-dimer levels are highly
associated with functional exercise capacity and may serve as a useful marker for
noninvasive monitoring. Further coagulation assays are needed to complete our
observations.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Bronchiolitis obliterans syndrome (BOS) is a serious compli-
cation of lung transplantation, affecting about 40% of
patients by 2 years after surgery.1–5 Multiple factors have
been implicated in the development of BOS,6–8 including the
number and severity of acute rejection episodes, cytome-
galo-virus infection, and HLA mismatching.9
Chronic allograft rejection is often associated with the
presence of fibrin thrombi in the microcirculation.10
Persistent fibrin deposition has been reported in affected
patients after kidney and cardiac transplantation.11,12
Moreover, Segal et al.12 observed that the presence of
plasma coagulation markers predicted the occurrence of
cardiac rejection. On the basis of these findings and the
increasing use of D-dimer, a degradation product of fibrin, as
a marker and prognostic factor in various thrombotic
diseases,13,14 we hypothesized that the severity of BOS in
lung transplant recipients is correlated with the activation
of coagulation and fibrinolysis and, hence, higher D-dimer
levels. The aim of the study was to determine if D-dimer
levels can be used as a noninvasive and rapid marker of the
severity of BOS, as measured by pulmonary exercise
capacity parameters.Patients and methods
Study subjects
All patients who underwent lung transplantation at Rabin
Medical Center between January 1997 and May 2006 were
screened for BOS. Forty-six patients (29%) had findings of
deteriorating allograft function and were included in the
study. All were clinically diagnosed with BOS stage 1a or
higher on the basis of the criteria of the International
Society for Heart and Lung Transplantation, as follows: a
decline of at least 20% in forced expiratory volume in 1 s
(FEV1) from their individual maximum post-transplant value,
in the absence of acute infection or acute rejection.15 Acute
infection was defined as a positive blood or sputum culture
in the presence of fever, a new pulmonary infiltrate, or new-
onset symptoms of cough, shortness of breath, and sputum
production. Gastroesophageal reflux disease was diagnosed
by 24-h pH monitoring and gastroscopy. Treatment consisted
of augmented immunosuppression in all cases.
Immunosuppression before 1998 included a combination
of prednisone, azathioprine, and cyclosporine; immunosup-
pression after November 1998 included prednisone, myco-
phenolate mofetil and tacrolimus. Follow-up after
transplantation consisted of routine clinic visits at least
every 4 weeks, with complete blood counts, blood chem-istry, drug level measurements, chest radiographs, pulmon-
ary function testing, and surveillance bronchoscopy.
The Institutional Human Subjects Review Board approved
the study protocol.
Sample collection and D-dimer assay
Following the diagnosis of BOS, blood samples were
collected into test tubes containing 3.2% buffered sodium
citrate. Platelet-poor plasma was separated by centrifuga-
tion within 4 h of collection and frozen at 70 1C. Prior to
analysis, all samples were rapidly thawed at 37 1C and
recentrifuged at 5000 rpm for 5min. D-dimer levels were
measured with the MiniQuant D-dimer assay (Biopool
International, Venture, CA) according to the manufacturer’s
instructions. All sample batches were assayed together with
controls purchased from the manufacturer. Normal levels
are below 150mg/ml.
Pulmonary function test
The pulmonary function test included spirometry, lung
volume, maximal voluntary ventilation, and diffusion
capacity.16 Measurements were corrected for body tem-
perature and pressure, saturated with water vapor. Testing
was performed with the Medical Graphics Pulmonary
Function System (1070-series 2, St. Paul, MN). Lung volumes
were obtained by body plethysmography (model 1085,
Medical Graphics, St. Paul, MN). Maximal voluntary ventila-
tion was assessed by asking the patient to breathe as fast
and as deeply as possible for 12 s, and the result was
multiplied by 5. Diffusion capacity of carbon monoxide was
measured by a single-breath technique with a gas mixture
containing air, 10% helium, and 0.3% carbon monoxide. Each
measurement was adjusted to standard temperature and
pressure. The predicted values of the parameters were
obtained from the regression equations of the European
Community for Coal and Steel.16
Cardiopulmonary exercise testing protocol17
Each participant underwent an incremental cardiopulmon-
ary exercise test according to the protocol of Wasserman
et al.18 on an electrically braked cycle ergometer (Ergoline
800, Germany). Testing was conducted between 8:30 and
12:00 a.m. noon. On arrival at the exercise laboratory,
patients were connected to a 12-lead electrocardiogram
(Cardiofax, Nihon Kohden, Tokyo, Japan) with a single-lead
(V5) monitor (VC-22, Nihon Kohden). Oxygen saturation
(SaO2) was measured by pulse oximetry (Nellcor NPB-190,
CA, USA) and blood pressure with a sphygmomanometer.
Patients were then positioned on the ergometer. After a
3-min rest period, patients performed unloaded pedaling for
2min at a rate of 60 rpm. The load was then progressively
increased by 15W/min (i.e., ramp protocol). The duration
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Table 1 Demographic data of the lung transplant
recipients with bronchiolitis obliterans syndrome
(n ¼ 46).
Parameter Value
Males (n, %) 32 (69)
Age (years) (mean7S.D.) 57710
Disease (n)
Emphysema 21
D-dimer in lung transplantation 207of the test was symptom-limited; the end-point of the
protocol was defined as the point in which the patient could
not maintain a pedaling rate of more than 40 rpm.
Cardiopulmonary data were collected and analyzed by an
exercise metabolic unit (CPX, Medical Graphics, St. Paul,
MN, USA). Heart rate, minute ventilation, tidal volume,
oxygen consumption, carbon dioxide production, oxygen
pulse and oxygen saturation were recorded and calculated
over 30-s intervals using standard formulas. Blood pressure
was measured with a sphygmomanometer and every 2min
until peak exercise.IPF 18
PPH 2
Sarcoidosis 2
Other 3
Time after LTX (months) (mean7S.D.) 2075The 6-min walk test
The 6-min walk test (6MWT) protocol was performed
according to the guidelines of the American Thoracic
Society.19Type of LTX (n)
Single 35
Double 7
Heart–lung 4
Immunosuppression (n)
FK-506 (tacrolimus) 36Study protocol
The association of the D-dimer levels with the clinical and
demographic variables, pulmonary function tests, 6MWT,
and cardiopulmonary parameters was evaluated. All the
technical assistants were blinded to the D-dimer levels.CsA 10
All data are n (%), unless otherwise indicated.
CsA: cyclosporine; DLT: double lung transplantation; FK:
tacrolimus (FK 506); LTX: lung transplantation; IPF: idio-
pathic pulmonary fibrosis; MMF: mycophenolate mofetil;
PPH: primary pulmonary hypertension.
Table 2 Clinical and functional exercise data of the
lung transplant recipients with bronchiolitis obliterans
syndrome (n ¼ 46).Statistical analysis
Results are shown as mean7S.D. Pearson correlation
coefficient (r) and the significance for it (p) were calculated
between the variables.
To analyze differences in the distribution of categorical
data, w2 test or Fisher exact test was used, as appropriate.
To predict BOS, a stepwise logistic regression was fitted to
the data. Odds ratios and 95% confidence intervals were
calculated from the model.
A p-value of 0.05 or less was considered statistically
significant.Parameter Value (mean7S.D.)
FEV1 (%) 62722
FEV1 (l) 1.8370.73
FEF 25–75 (%) 47729
FEF 25–75 (l) 1.5671.0
DLCO (%) 57719
Saturation (%) 9272.0
6MWD (m) 404783
Respiratory reserve 32720
VO2/kg (ml/kg/min) 13.573.8
D-dimer (mg/ml) 2987484
DLCO: diffusion capacity of CO; FEF 25–75: forced expiratory
flow at 25–75%; FEV1: forced expiratory volume at 1 s; 6MWD:
6-min walk distance; VO2: oxygen consumption.Results
Clinical characteristics
Table 1 summarizes the demographic characteristics of the
lung transplant recipients with BOS. Most of the patients
(n ¼ 39, 85%) underwent lung transplantation because of
chronic obstructive pulmonary disease and pulmonary
fibrosis. Thirty-five patients (76%) underwent single-lung
transplantation. All patients were treated with corticoster-
oids and 36 (78%) with a FK 506-based regimen.
Table 2 summarizes the clinical characteristics of the
patients, including pulmonary lung function and results of
the cardiopulmonary exercise test and 6MWT. Most of the
patients had mild to moderate lung function abnormalities
with preserved saturation and exercise tolerance.Correlations between D-dimer and study
parameters
Table 3 and Figure 1 show the Pearson correlation coefficient
(r) and the significance for it (p) between D-dimer values
and the study variables.D-dimer levels were correlated with age (r ¼ 0.34,
p ¼ 0.02), FEV1 (r ¼ 0.43, p ¼ 0.001), 6MWT (r ¼ 0.53,
p ¼ 0.04) and VO2/kg/min (r ¼ 0.36, p ¼ 0.04).
No correlations were noted between D-dimer levels and
total lung capacity, diffusion capacity and oxygen satura-
tion. On multivariate logistic regression, only FEV1 was a
significant predictor of absence of BOS (OR 0.885, CI:
0.812–0.965).
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Table 3 Correlations of the study parameters with D-dimer
levels.
Parameters p-Value Pearson correlation
coefficient, r
Age 0.02 0.34
FEV1 0.001 0.43
FEF 25–75 0.42 0.12
DLCO 0.93 0.02
Saturation 0.59 0.09
6MWD 0.04 0.53
VO2/kg 0.04 0.36
DLCO: diffusion capacity of CO; FEF 25–75: forced expiratory
flow at 25–75%; FEV1: forced expiratory volume at 1 s; 6MWD:
6-min walk distance; VO2: oxygen consumption.
Figure 1 Correlations of D-dimer levels with functional
exercise capacity (VO2/kg) in lung transplant recipients with
chronic allograft rejection.
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Lung transplantation has emerged as an important ther-
apeutic option for patients with end-stage pulmonary
disease.20 Although short-term survival is improved with
transplantation, long-term survival is limited by the devel-
opment of BOS. Studies have shown that BOS occurs in
40–70% of recipients by 5 years after transplantation.15,21
For those who fail enhanced immunosuppressive regimens,
other treatment options are rarely successful. Although
most of the evidence suggests that BOS is immune-
mediated, many transplant recipients experience activation
of the coagulation and fibrinolytic systems that potentially
worsens chronic rejection.
This study demonstrates that high D-dimer levels are
associated with FEV1 as well as functional exercise capacity
in lung transplant recipients with BOS, as measured by
6MWT and VO2/kg/min. These results have two major
implications. First, the relationship offers possible evidence
of a pathophysiological link between BOS and hypercoagu-
lative state. Second, higher levels of D-dimer in lung
transplant recipients may identify those at being at higher
risk of BOS. Evidence of a link between allograft function
and hypercoagulability continues to accumulate, especially
in renal transplant recipients.10,22 In renal transplantation,endothelial cells form the interface between donor and
recipient tissues. Antibody or thrombin-stimulated endothe-
lium produces platelet-activating factor, and thrombin-
stimulated endothelium releases both plasminogen activa-
tors and plasminogen activator inhibitors (PAI-I). Therefore,
allograft recognition may initiate clotting and fibrinolytic
phenomena which, in turn, cause monocytes and macro-
phages to produce tissue factor, a potent initiator of
coagulation. Endothelial cells can also be stimulated to
elaborate tissue factor by immune complexes, interleukin-1,
or endotoxin. Christie et al.23 assessed the role of protein C
type 1 PAI-I levels in plasma of lung transplant recipients
with primary graft dysfunction (PGD). They found lower
postoperative protein C and higher PAI-I plasma levels are
associated with PGD after lung transplantation. Impaired
fibrinolysis and enhanced coagulation may be important in
PGD pathogenesis. These observations give cause to spec-
ulate that the link between immunity and coagulation could
be products of allogenic recognition that activate factor VII
and lead to fibrin deposition. This suggests new approaches
of diagnosis and treatment of rejection reactions in organ
transplantation.22
Segal et al.,12 in a study of plasma markers of coagulation
in cardiac transplant recipients, found that p-selectin and
prothrombin fragment levels significantly predicted organ
rejection. The authors suggested that these markers may be
useful for noninvasively monitoring patients for allograft
rejection or response to treatment.
The influence of rejection on fibrinolytic regulators was
also assessed by Perkowska et al.10 in 64 patients who
underwent kidney transplantation from cadaveric allograft
donors.10 They found significantly higher levels of tissue
plasminogen activator (tPA) and lower levels of PAI-I than in
healthy controls. Among the transplant recipients, PAI-I
level was significantly higher in the patients with graft
rejection than in the patients with stable graft function. The
authors concluded that chronic allograft rejection is
apparently associated with an increase PAI-I activity.10
An important immunocytochemical study of biopsy tissue
from 68 transplanted hearts revealed that depleted arter-
iolar tPA was significantly associated with vascular and
interstitial deposits of fibrin, plasmin, and endothelial
tPA–PAI-I complexes.24 These findings indicate that hemo-
static and fibrinolytic pathways are activated in failing
allografts, and that they can supply evidence of depleted
tPA even before clinical or histopathological signs of failure.
Our study assessed patients with BOS syndrome. This is
common and potentially devastating. Its exact cause is
undefined, but multiple immune and nonimmune processes
contribute to its pathogenesis. Severe acute rejection and
recurrent acute rejection have been shown to confer the
greatest risk for the syndrome, signifying the central
importance of alloimmunity in the disease process. As our
understanding of the disease evolves, it is hoped that
effective interventions targeted at specific pathogenetic
steps will emerge. In the meantime, obliterative bronchio-
litis remains the most important and sinister long-term
complication of lung transplantation. Although the diagnosis
of the syndrome based on the pathological stage, the
clinical presentations are critical for the diagnosis.
Our study, though limited by the small sample size, the
lack of serial D-dimer tests and other coagulation markers
ARTICLE IN PRESS
D-dimer in lung transplantation 209and data concerning the other lung transplant recipients has
important advantages. First, the available data on the role
of noninvasive markers in patients with allograft rejec-
tion25–27 are limited, and to the best of our knowledge, our
study is the first to assess the role of D-dimer assay, a
fibrinolytic marker, in lung transplantation. Second, the
statistically significant correlation between D-dimer level
and functional exercise capacity in lung transplant recipi-
ents with BOS, as measured by FEV1, 6MWTand VO2/kg/min,
highlights the important involvement of the coagulation
pathway in allograft rejection.
In summary, our findings suggest that the simple,
noninvasive D-dimer test may have an important place in
the evaluation of lung transplant recipients with BOS.
Further coagulation assays are needed to complete our
observations.
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